Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease
This research supports the effectiveness of IVR for ROP II2+ over a one-year period. The links between lower birth weight and both reactivation and PAR might guide refinements in therapeutic strategies.
Authors
- Atsushi Uchiyama (ORCID: https://orcid.org/0000-0003-0339-8571)
- Takahiro Suzuki (ORCID: https://orcid.org/0000-0002-7949-5477)
- Yoshihiro Nakagawa
- Yasuyuki Suzuki
- Yoshifumi Murayama
Institutions
- Tokai University (JP)
Publication Details
- Journal
- Japanese Journal of Ophthalmology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1007/s10384-025-01199-y
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00